Background/Aims: Mutations in the human growth hormone receptor gene (GHR) are the most common cause of growth hormone insensitivity (GHI) syndrome and insulin-like growth factor (IGF-1) deficiency. The extracellular domain of GHR (encoded by exons 2-7 of the GHR gene) can be proteolytically cleaved to circulate as GH-binding protein (GHBP). Methods: We evaluated the cause of classical GHI (Laron) phenotypes in 3 siblings. Results: Two brothers (aged 16.5 and 14.9 years) and their half-brother (aged 11.3 years) presented with extreme short stature (height standard deviation score, SDS, of -7.05, -6.34 and -8.02, respectively). The parents were consanguineous and of normal stature. Serum GHBP levels of probands were undetectable and circulating IGF-1 and IGF-binding protein-3 were abnormally low, but GH concentrations were elevated. Molecular analysis of the GHR gene revealed homozygous deletion of exon 3, a common polymorphism, and a novel c.266+83G>T variant within intron 4 which generated a 5′ donor splice site. Splicing events from this cryptic 5′ donor site resulted in retention of 81 intronic nucleotides in the GHR mRNA. Long-term rhIGF-1 therapy combined with leuprolide depot increased height by +2 to +3 SDS. Conclusion: The c.266+83G>T is the second intronic GHR mutation identified that activates a cryptic 5′ donor splice site. The abnormal splicing event led to early protein termination and undetectable serum GHBP concentrations.

1.
David A, Hwa V, Metherell LA, Netchine I, Camacho-Hubner C, Clark AJ, Rosenfeld RG, Savage MO: Evidence for a continuum of genetic, phenotypic, and biochemical abnormalities in children with growth hormone insensitivity. Endo Rev 2011;32:472-497.
2.
Laron Z, Pertzelan A, Mannheimer S: Genetic pituitary dwarfism with high serum concentration of growth hormone - a new inborn error of metabolism? Isr J Med Sci 1966;2:152-155.
3.
Rosenfeld RG, Rosenbloom AL, Guevara-Aguirre J: Growth hormone (GH) insensitivity due to primary GH receptor deficiency. Endocr Rev 1994;15:369-390.
4.
Rosenbloom AL: Physiology and disorders of the growth hormone receptor (GHR) and GH-GHR signal transduction. Endocrine 2000;12:107-119.
5.
Rowlinson SW, Yoshizato H, Barclary JL, Brooks AJ, Behncken SN, Kerr LM, Millard K, Palethorpe K, Nielsen K, Clyde-Smith J, Hancock JF, Waters MJ: An agonist-induced conformational change in the growth hormone receptor determines the choice of signalling pathway. Nat Cell Biol 2008;10:740-747.
6.
de Vos AM, Ultsch M, Kossiakoff AA: Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 1992;255:306-312.
7.
Behncken SN, Waters MJ: Molecular recognition events involved in the activation of the growth hormone receptor by growth hormone. J Mol Recognit 1999;12:355-362.
8.
Brown RJ, Adams JJ, Pelekanos RA, Wan Y, Mckinstry WJ, Palethorpe K, Seeber RM, Monks TA, Eidne KA, Parker MW, Waters MJ: Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol 2005;12:814-821.
9.
Woods KA, Fraser NC, Postel-Vinay MC, Savage MO, Clark AJ: A homozygous splice site mutation affecting the intracellular domain of the growth hormone (GH) receptor resulting in Laron syndrome with elevated GH-binding protein. J Clin Endocrinol Metab 1996;81:1686-1690.
10.
Silbergeld A, Dastot F, Klinger B, Kanety H, Eshet R, Amselem S, Laron Z: Intronic mutation in the growth hormone (GH) receptor gene from a girl with Laron syndrome and extremely high serum GH binding protein: extended phenotypic study in a very large pedigree. J Pediatr Endocrinol Metab 1997;10:265-274.
11.
Aalbers AM, Chin D, Pratt KL, Little BM, Frank SJ, Hwa V, Rosenfeld RG: Extreme elevation of serum growth hormone-binding protein concentrations resulting from a novel heterozygous splice site mutation of the growth hormone receptor gene. Horm Res 2009;71:276-284.
12.
David A, Miraki-Moud F, Shaw NJ, Savage MO, Clark AJ, Metherell LA: Identification and characterisation of a novel GHR defect disrupting the polypyrimidine tract and resulting in GH insensitivity. Eur J Endocrinol 2010;162:37-42.
13.
Derr MA, Aisenberg J, Fang P, Tenenbaum-Rakover Y, Rosenfeld RG, Hwa V: The growth hormone receptor (GHR) c.899dupC mutation functions as a dominant negative: insights into the pathophysiology of intracellular GHR defects. J Clin Endocrinol and Metab 2011;PMID:21900382.
14.
Derr MA, Fang P, Sinha SK, Ten S, Hwa V, Rosenfeld RG: A novel Y332C missense mutation in the intracellular domain of the human growth hormone receptor (GHR) does not alter STAT5b signaling: redundancy of GHR intracellular tyrosines involved in STAT5b signaling. Horm Res 2011;75:187-199.
15.
Ayling RM, Ross R, Towner P, Von Laue S, Finidori J, Moutoussamy S, Buchanan CR, Clayton PE, Norman MR: A dominant-negative mutation of the growth hormone receptor causes familial short stature. Nat Genet 1997;16:13-14.
16.
Iida K, Takahashi Y, Kaji H, Nose O, Okimura Y, Abe H, Chihara K: Growth hormone (GH) insensitivity syndrome with high serum GH-binding protein levels caused by a heterozygous splice site mutation of the GH receptor gene producing a lack of intracellular domain. J Clin Endocrinol Metab 1998;83:531-537.
17.
Fang P, Riedl S, Amselem S, Pratt KL, Little BM, Haeusler G, Hwa V, Frisch H, Rosenfeld RG: Primary growth hormone (GH) insensitivity insulin-like growth factor deficiency caused by novel compound heterozygous mutations of the GH receptor gene: genetic and functional studies of simple and compound heterozygous state. J Clin Endocrinol Metab 2007;92:2223-2231.
18.
Metherell LA, Akker SA, Munroe PB, Rose SJ, Caulfield M, Savage MO, Chew SL, Clark AJ: Pseudoexon activation as a novel mechanism for disease resulting in atypical growth-hormone insensitivity. Am J Hum Genet 2001;69:641-646.
19.
Fang P, Cho YH, Derr MA, Rosenfeld RG, Hwa V, Cowell CT: Severe short stature caused by novel compound heterozygous mutations of the insulin-like growth factor 1 receptor (IGF1R). J Clin Endocrinol and Metab 2012;97:E243-E247.
20.
Kofoed EM, Hwa V, Little B, Woods KA, Buckway CK, Tsubaki J, Pratt KL, Bezrodnik L, Jasper H, Tepper A, Heinrich J, Rosenfeld RG: Growth-hormone insensitivity (GHI) associated with a STAT-5b mutation. N Engl J Med 2003;349:1139-1147.
21.
Woods KA, Dastot F, Preece MA, Clark AJ, Postel-Vinay MC, Chatelain PG, Ranke MB, Rosenfeld RG, Amselem S, Savage MO: Phenotype: genotype relationships in growth hormone insensitivity syndrome. J Clin Endocrinol Metab 1997;82:3529-3535.
22.
Akinci A, Rosenfeld RG, Hwa V: A novel exonic GHR splicing mutation (c.784G>C) in a patient with classical growth hormone insensitivity syndrome. Horm Res Paediatr 2013;79:32-38.
23.
Amselem S, Duquesnoy P, Duriez B, Dastot F, Sobrier M-L, Valleix S, Goossens M: Spectrum of growth hormone receptor mutations and associated haplotypes in Laron syndrome. Hum Mol Genet 1993;2:355-359.
24.
Otsuka T, Iwatani N, Kodama M, Sakakida M, Shichiri M, Jinno Y, Niikawa N, Miike T: The growth hormone receptor gene mutation of a Japanese patient with Laron syndrome. Jpn J Hum Genet 1997;42:323-329.
25.
Berg MA, Guevara-Aguirre J, Rosenbloom AL, Rosenfeld RG, Francke U: Mutation creating a new splice site in the growth hormone receptor genes of 37 Ecuadorean patients with Laron syndrome. Hum Mutat 1992;1:24-32.
26.
Sobrier ML, Dastot F, Duquesnoy P, Kandemir N, Yordam N, Goossens M, Amselem S: Nine novel growth hormone receptor gene mutations in patients with Laron syndrome. J Clin Endocrinol Metab 1997;82:435-437.
27.
Baumbach L, Schiavi A, Bartlett R, Perera E, Day J, Brown MR, Stein S, Eidson M, Parks JS, Cleveland W: Clinical, biochemical, and molecular investigations of a genetic isolate of growth hormone insensitivity (Laron's syndrome). J Clin Endocrinol and Metab 1997;82:444-451.
28.
David A, Camacho-Hubner C, Bhangoo A, Rose SJ, Miraki-Moud F, Akker SA, Butler GE, Ten S, Clayton PE, Clark AJ, Savage MO, Metherell LA: An intronic growth hormone receptor mutation causing activation of a pseudoexon is associated with a broad spectrum of growth hormone insensitivity phenotypes. J Clin Endocrinol and Metab 2007;92:655-659.
29.
Marin S, Casano-Sancho P, Villarreal-Pena N, Sebastiani G, Pinillos S, Perez-Duenas B, Hwa V, Rosenfeld RG, Ibanez L: Triple A syndrome in a patient with genetic growth hormone insensitivity: phenotypic effects of two genetic disorders. Horm Res Paediatr 2012;77:63-68.
30.
Wang G-S, Cooper TA: Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet 2007;8:749-761.
31.
Wang Z, Burge CB: Splicing regulation: from a parts list of regulatory elements to an integrated splicing code. RNA 2008;14:802-813.
32.
Laron Z: Laron-Type Dwarfism (Hereditary Somatomedin Deficiency): A Review. Berlin, Springer, 1984.
33.
McKay SD, Al-Omari A, Tomlinson LA, Dormans JP: Review of cervical spine anomalies in genetic syndromes. Spine 2012;37:E269-E277.
34.
Kornreich L, Horev G, Schwarz M, Karmazyn B, Laron Z: Laron syndrome abnormalities: spinal stenosis, os odontoideum, generative changes of the Atlanto-odontoid joint and small oropharynx. Am J Neuroradiol 2002;23:625-631.
35.
Bhatia K, Cockerham R: Anaesthetic management of a parturient with Laron dwarfism. Int J Obstet Anesth 2011;20:344-346.
36.
Woods KA, Camacho-Hubner C, Savage MO, Clark AJ: Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. New Engl J Med 1996;335:1363-1367.
37.
Walenkamp MJE, Karperien M, Pereira AM, Hilhorst-Hofstee Y, van Doorn J, Chen JW, Mohan S, Denley A, Forbes BE, van Duyvenvoorde H, van Thiel SW, Sluimers CA, Bax JJ, de Laat JA, Breuning MB, Romijn JA, Wit JM: Homozygous and heterozygous expression of a novel insulin-like growth factor-I mutation. J Clin Endocrinol and Metab 2005;90:2855-2864.
38.
Netchine I, Azzi S, Houang M, Seurin D, Perin L, Ricot J-M, Daubas C, Legay C, Mester J, Herich R, Godeau F, Le Bouc Y: Partial primary deficiency of insulin-like growth factor (IGF)-I activity associated with IGF1 mutation demonstrates its critical role in growth and brain development. J Clin Endocrinol and Metab 2009;94:3913-3921.
39.
Backeljauw PF, Underwood LE: Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study. J Clin Endocrinol and Metab 2001;86:1504-1510.
40.
Besson A, Salemi S, Eble A, Joncourt F, Gallati S, Jorge AAL, Mullis PE: Primary GH insensitivity (Laron syndrome) caused by a novel 4 kb deletion encompassing exon 5 of the GH receptor gene: effect of intermittent long-term treatment with recombinant human IGF-I. Eur J Endocrinol 2004;150:635-642.
41.
Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE; Group GISC: Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol and Metab 2007;92:902-910.
42.
Collett-Solberg PF, Misra M: The role of recombinant human insulin-like growth factor-I in treating children with short stature. J Clin Endocrinol and Metab 2008;93:10-18.
43.
Midyett LK, Rogol AD, Van Meter QL, Frane J, Bright GM: Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: first year results from a randomized clinical trial. J Clin Endocrinol and Metab 2010;95:611-619.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.